Kaira Kyoichi, Sunose Yutaka, Arakawa Kazuhisa, Sunaga Noriaki, Shimizu Kimihiro, Tominaga Hideyuki, Oriuchi Noboru, Nagamori Shushi, Kanai Yoshikatsu, Oyama Tetsunari, Takeyoshi Izumi
Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma, Japan; Department of Diagnostic Pathology, Gunma University Graduate School of Medicine, Gunma, Japan.
Histopathology. 2015 Jan;66(2):234-43. doi: 10.1111/his.12464. Epub 2014 Dec 23.
ASC amino acid transporter-2 (ASCT2) is highly expressed in cancer cells. However, the clinicopathological significance of ASCT2 expression in pancreatic cancer remains unclear. The aim of this study was to investigate the clinical significance of ASCT2 expression in pancreatic cancer.
Ninety-seven patients with surgically resected pancreatic ductal adenocarcinoma were evaluated. Tumour sections were stained by immunohistochemistry for ASCT2, Ki67, CD34 (to determine microvessel density), phospho-AKT (p-AKT) and phospho-mammalian target of rapamycin (p-mTOR) expression. ASCT2 was expressed in 54% (52/97) of tumours. Statistically significant differences in patient age, T stage, N stage, lymphatic permeation, vascular invasion, Ki67, and CD34 and p-mTOR expression were observed between tumours with and without ASCT2 expression. Multivariate analysis confirmed that vascular invasion, ASCT2 expression and Ki67 expression were independent predictive factors for a poorer prognosis.
ASCT2 expression plays an important role in tumour cell growth, and is a promising pathological marker for predicting a worse outcome in pancreatic cancer.
ASC氨基酸转运体2（ASCT2）在癌细胞中高表达。然而，ASCT2表达在胰腺癌中的临床病理意义仍不清楚。本研究的目的是探讨ASCT2表达在胰腺癌中的临床意义。
对97例接受手术切除的胰腺导管腺癌患者进行评估。肿瘤切片通过免疫组织化学染色检测ASCT2、Ki67、CD34（用于确定微血管密度）、磷酸化AKT（p-AKT）和磷酸化雷帕霉素哺乳动物靶蛋白（p-mTOR）的表达。54%（52/97）的肿瘤表达ASCT2。在有和没有ASCT2表达的肿瘤之间，观察到患者年龄、T分期、N分期、淋巴浸润、血管侵犯、Ki67以及CD34和p-mTOR表达存在统计学显著差异。多因素分析证实，血管侵犯、ASCT2表达和Ki67表达是预后较差的独立预测因素。
ASCT2表达在肿瘤细胞生长中起重要作用，是预测胰腺癌预后较差的一个有前景的病理标志物。
